B3 Lesions (Lesions of Uncertain Malignant Potential)
General concept
- Definition: Breast lesions identified on Core Needle Biopsy (CNB) that are benign but have a heterogeneous histology with an increased risk of associated malignancy (DCIS or invasive cancer) in the surrounding tissue ("upgrade rate") or an increased long-term risk of developing breast cancer.
- Histological Classification (NHS BSP):
- B3a: Without epithelial atypia (e.g., typical papilloma, radial scar, cellular fibroepithelial lesions).
- B3b: With epithelial atypia (e.g., ADH, classic LCIS, FEA).
Specific entities
1. Atypical Intraductal Proliferation (AIDP)
- Atypical ductal hyperplasia (ADH):
2. Lobular Neoplasia (LN)
- Spectrum: Atypical Lobular Hyperplasia (ALH) and Lobular Carcinoma in Situ (LCIS).
- Classic LCIS:
- Generalized risk factor (marker) rather than a direct precursor (though some debate exists).
- Management: Diagnostic excision (VAE or open) to rule out synchronous cancer. If concordant and classic type: Surveillance (Annual mammography).
- Pleomorphic LCIS / Florid LCIS:
- Behaves like high-grade DCIS (comedo-necrosis).
- Management: Surgical excision with clear margins is mandatory (treated like DCIS).
3. Flat Epithelial Atypia (FEA)
- Definition: Dilated ducts lined by a single layer of columnar cells with low-grade atypia (Columnar Cell Change with Atypia).
- Association: Frequently associated with low-grade DCIS and tubular carcinoma.
- Upgrade rate: Lower (~5–10%).
- Management: VAE. If no malignancy found on VAE, surveillance is appropriate.
4. Papillary lesions
5. Radial Scar / CSL
- See Radial scar.
- B3a (if no atypia) or B3b (if associated with ADH/FEA).
- Management: Excision required (VAE or surgery).
6. Fibroepithelial lesions (Cellular)
- Distinction between fibroadenoma and Benign phyllodes tumor can be difficult on CNB.
- If reported as "Cellular fibroepithelial lesion" or "Phyllodes cannot be excluded":
- Management: Excision (usually surgical with margins for Phyllodes).
Management algorithm (NHS BSP / RCR Consensus)
The "Second-Line" Procedure
A B3 result on CNB always triggers further action. Discharge is never the immediate next step.
- MDT Discussion: Mandatory. Radiologic-pathologic correlation is critical.
- Vacuum Assisted Excision (VAE):
- First-line for most B3 lesions (papilloma, radial scar, FEA, classic LCIS) to obtain larger tissue volume (4g tissue or clear radiologic removal).
- Therapeutic: Removes the lesion entirely.
- Diagnostic: Excludes adjacent malignancy.
- Surgical Excision:
- Indicated for ADH (standard care), Pleomorphic LCIS, Phyllodes tumor, or if VAE is technically not feasible (lesion too posterior/thin breast).
- Indicated if VAE pathology shows upgrade to malignancy.
- Surveillance:
- Only initiated after VAE/Surgery confirms no invasive cancer or DCIS.
- Protocol: Annual mammography for 5 years (standard UK protocol).
Comparison of management (Exam focus)
| Entity | Atypia present? | Primary Management (Exam Answer) |
|---|---|---|
| Radial Scar | No | VAE (excision) |
| Papilloma | No | VAE (excision) |
| FEA | Yes (low grade) | VAE (excision) |
| ADH | Yes | Surgical Excision (or extensive VAE) |
| Classic LCIS | Yes | VAE -> Surveillance |
| Pleomorphic LCIS | Yes (high grade) | Surgical Excision (with margins) |
| Cellular FA | No | Excision (Surgery often preferred if phyllodes concern) |
Exam pearls
- Common Scenario: 50F, screening mammogram shows microcalcifications. CNB shows FEA.
- Next step: VAE. (Reason: FEA is associated with low-grade DCIS/Tubular carcinoma in adjacent tissue).
- The "Upgrade" Trap:
- Exam questions often ask for the "highest risk of upgrade".
- ADH usually has the highest upgrade rate among B3 lesions (up to 30%).
- Mucocele-like lesions (MLL):
- Rare B3 lesion.
- Mucin-filled cysts requiring differentiation from mucinous carcinoma.
- If atypia present -> Excision.
- Discordance: If imaging looks malignant (BI-RADS 5) but biopsy is B3 -> Diagnostic Surgical Excision is mandatory regardless of B3 subtype.
